Preventing tumor cell migration, limiting metastatic burden, and enhancing anti-tumor immune activities to overcome resistance to standard therapies (Peng et al., 2025), blocking CXCR4 signaling is the way (Eckert et al., 2018). The gene discussed is CXCR4; the disease is neoplasm.